KRAS and acute myeloid leukemia: Age, gender, type of AML, previous treatment in CR1 with autologous or allogeneic HCT, mutational status of NPM1, DNMT3A, TET2, NRAS, KRAS, IDH1, IDH2, TP53, FLT3-TKD and of genes coding for chromatin/spliceosome complex were not significantly correlated with achievement of a second CR/CRi.